Natural Alternatives International, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark A. LeDoux
- Full Time Employees
- 293
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Address
- 1535 Faraday Avenue Carlsbad CA United States of America 92008
- IPO Date
- Oct 28, 1993
- CIK
- 0000787253
- Website
- nai-online.com
- Similar Companies
- Business
- Natural Alternatives International, Inc. (NAII) formulates, manufactures, and markets customized nutritional supplements worldwide through its private-label contract manufacturing and patent and trademark licensing segments; it provides comprehensive services including custom formulation, scientific research, proprietary ingredients such as CarnoSyn beta-alanine and SR CarnoSyn sustained-release beta-alanine, product testing and evaluation, packaging and delivery system design, regulatory review, international product registration assistance, weighing and blending, material receiving, QA testing, finished goods packaging, stability programs, and warehousing. The company offers vitamins, minerals, herbs, and other healthcare products, with a focus on sports nutrition, wellness, healthy aging, and plant-based solutions like those for The Juice Plus+ Company, targeting brands and distributors in over 24 global markets. Founded in 1980 by Mark A. LeDoux and headquartered in Carlsbad, California, NAII operates manufacturing facilities in the United States, Switzerland via Natural Alternatives International Europe SA, and supports international operations including Japan. In July 2025, NAII extended its over 30-year partnership with The Juice Plus+ Company through a new multi-year manufacturing agreement for capsule and powder products sold globally. In 2024, the company and CarnoSyn Brands launched TriBsyn, a novel carnosine booster designed to enhance beta-alanine bioavailability and absorption while minimizing paresthesia; additionally, in 2023, it opened a state-of-the-art high-volume blending and packaging facility in Carlsbad, California, following its 2021 acquisition of the site.
Natural Alternatives International (NASDAQ:NAII) Stock Crosses Below 200 Day Moving Average – Here’s What Happened
Natural Alternatives Q3 Loss Widens Y/Y on Margin Pressure
Natural Alternatives International, Inc. Announces 2026 Q3 and YTD Results
Natural Alternatives International (NASDAQ:NAII) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?
Natural Alternatives Q2 Loss Widens Y/Y, Sales Increase
Natural Alternatives International, Inc. Announces 2026 Q2 and YTD Results
Niche Focus & Regulation Shape the Future of Healthcare Firms
Natural Alternatives International (NASDAQ:NAII) Share Price Passes Above Fifty Day Moving Average – What’s Next?
Natural Alternatives International (NASDAQ:NAII) Stock Crosses Below 200 Day Moving Average – Here’s What Happened
Natural Alternatives International, Inc. Announces 2026 Q1 Results
Zacks Initiates Coverage of NAII With Neutral Recommendation
Natural Alternatives International, Inc. Announces Fiscal 2025 Q4 and YTD Results
Natural Alternatives International, Inc. Announces New Manufacturing Agreement with The Juice Plus+® Company
Natural Alternatives International, Inc. Announces Amended and Extended Credit Facility with Wells Fargo Bank
Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination
Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results
Natural Alternatives International, Inc. Announces 2025 Q1 Results
CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients
Natural Alternatives International, Inc. Announces Fiscal 2024 Q4 and YTD Results